Ronald C. Renaud Jr.

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
Cambridge, MA
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ Allison Ambrose, Attorney-in-Fact
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Ronald C. Renaud Jr.

Form 4 holding President & CEO, Director

Cerevel Therapeutics Holdings, Inc.

Security class
Performance-based Restricted Stock Units
Shares / value
0
Estimated value
$0
Report date
01 Aug 2024
Price
$41.18
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding President & CEO, Director

Cerevel Therapeutics Holdings, Inc.

Security class
Restricted Stock Units
Shares / value
0
Estimated value
$0
Report date
01 Aug 2024
Price
$41.18
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding CEO & President, Director

Kailera Therapeutics, Inc.

Security class
Stock Option (right to buy)
Shares / value
817,826
Estimated value
Report date
09 Jun 2026
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Atara Biotherapeutics, Inc.

Security class
Non-Qualified Stock Option (Right to Buy)
Shares / value
31,500
Estimated value
Report date
23 Jun 2022
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Upstream Bio, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
17,096
Estimated value
Report date
09 Jun 2026
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Ikena Oncology, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
13,419
Estimated value
Report date
09 Jun 2022
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding President & CEO, Director

Cerevel Therapeutics Holdings, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
0
Estimated value
Report date
01 Aug 2024
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Chief Executive Officer, Director

Translate Bio, Inc.

Security class
Common Stock
Shares / value
0
Estimated value
Report date
14 Sep 2021
Price
$38.00
Ownership
By Ronald C. Renaud, Jr. Trust - 2007
Form 4 holding Chief Executive Officer, Director

Translate Bio, Inc.

Security class
Common Stock
Shares / value
0
Estimated value
Report date
14 Sep 2021
Price
$38.00
Ownership
By Ronald Renaud 2014 Irrevocable Family Trust
Form 4 holding Chief Executive Officer, Director

Translate Bio, Inc.

Security class
Common Stock
Shares / value
0
Estimated value
Report date
14 Sep 2021
Price
$38.00
Ownership
Direct
Form 4 holding Chief Executive Officer, Director

Translate Bio, Inc.

Security class
Stcok Option (right to buy)
Shares / value
0
Estimated value
Report date
14 Sep 2021
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Chief Executive Officer, Director

Translate Bio, Inc.

Security class
Stock Option (right to buy)
Shares / value
0
Estimated value
Report date
14 Sep 2021
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Ronald C. Renaud Jr.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .